Brought to you by 
Cephalon sells $750mm in convertible debt offering
19 Jun 2003
Executive Summary
Neurology, cancer, and sleep therapeutics company Cephalon announced the completion of its sale of $750mm in zero coupon convertible subordinated notes due 2033, priced at 100% of their principal amount.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Convertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cephalon sells $750mm in convertible debt offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice